JM Financial has retained its Buy rating on Metropolis Healthcare with a target price of Rs 734, implying 27.2% upside. The brokerage calls it the cheapest among India’s leading listed diagnostic players, citing attractive valuations, network expansion, stronger B2C growth and improving margins as key drivers.
Market Samachar is a news aggregator. This article was originally published by Stocks-Markets-Economic Times. Tap the button above to read the full story on their site.